Article info
PDFPostScript
PostScript
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis
- Correspondence to Dr Jian-Hong Zhong, Hepatobiliary Surgery Department, Guangxi Medical University Cancer Hospital, Nanning 530021, China; zhongjianhong66{at}163.com
Citation
Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis
Publication history
- Received November 20, 2019
- Revised December 3, 2019
- Accepted December 3, 2019
- First published December 16, 2019.
Online issue publication
December 06, 2020
Article Versions
- Previous version (7 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.